podcast
Investment Companies
edison tv
Investment Companies
“Edison is the go-to for a new investor to get full understanding of the investment case and business. Edison’s distribution reaches investors that we want to connect with directly.”
OSE Immunotherapeutics has announced the initiation of the much-awaited Phase III registrational study for lead asset Tedopi, the most advanced therapeutic cancer vaccine currently in development. The pivotal study, termed Artemia, will be a randomised, open-label trial evaluating Tedopi as a second-line monotherapy for HLA-A2 positive patients with metastatic non-small cell lung cancer. We note that the study will focus on patients with secondary resistance to immune checkpoint inhibitors, a cohort that saw the maximum benefit in the preceding Atalante-1 trial. Top-line results are expected by 2027.
Healthcare | Comment
Consumer | Comment
Investment Companies | Comment
Healthcare | Comment
Healthcare | Comment
Get access to the very latest content matched to your personal investment style.